Teva Advances as Savings May Offset Competition: Tel Aviv Mover

Teva Pharmaceutical Industries Ltd. rose the most in seven months after Sanford C. Bernstein & Co. said cost savings could offset the effect of generic competition on sales of bestselling multiple sclerosis injection Copaxone.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.